merged_eli-lilly-zepbound-price.txt
<question_number>1</question_number>
<answer>By offering a cheaper, FDA-approved alternative</answer>
<question_number>2</question_number>
<answer>By providing a cheaper, FDA-approved version through a telehealth platform like LillyDirect</answer>
<question_number>3</question_number>
<answer>Lack of oversight and potential safety issues</answer>
<question_number>4</question_number>
<answer>To recapture market share from compounded drugs</answer>
<question_number>5</question_number>
<answer>It permits compounding pharmacies to produce alternatives while the drug is in shortage</answer>
<question_number>6</question_number>
<answer>N/A</answer>
<question_number>7</question_number>
<answer>Increased appeal to Medicare patients despite potential risks</answer>
<question_number>8</question_number>
<answer>It may lead patients to perceive official vials as safer</answer>
<question_number>9</question_number>
<answer>Being on the FDA's shortage list</answer>
<question_number>10</question_number>
<answer>Lowering prices</answer>